HENAN SUNLAKE ENTERPRISE CORPORATION
Free supplier Enterprise Certification
- Free
supplier - 9th
years
Free supplier Enterprise Certification
Product Certification&
Enterprise Certification
Country: 
China (Mainland)
Business Type:Trading Company
Tel: +86-371- 86259723
Tel: 17734809689
Tel: 17734809689
Tel: 86-371-86259723
Tel: 17734809689
Tel: 17734809689
Mobile: 17734809689
Tel: +86-371- 86259723
Fax: +86-371- 86259723
Province/state: HENAN
City: ZHENGZHOU
Street: Mingmen International Center, NO.222 Dongming Road,Zhengzhou,Henan,China
MaxCard:
Contact Suppliers
CAS NO.319460-85-0
1(10-100)Gram1(100-200)Gram
| Axitinib Basic information |
| Product Name: | Axitinib |
| Synonyms: | AXITINIB;Benzamide, N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-;N-METHYL-2-{[3-((E)-2-PYRIDIN-2-YLVINYL)-1H-INDAZOL-6-YL]SULFANYL}BENZAMIDE;N-Methyl-2-((3-((1E)-2-(pyridin-2-yl)ethenyl)-1H-indazol-6-yl)sulfanyl)benzamide;AVERMECTINB;Axitinib for research;AG 013736;N-Methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide |
| CAS: | 319460-85-0 |
| MF: | C22H18N4OS |
| MW: | 386.47 |
| EINECS: | |
| Product Categories: | All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Protein Kinase Inhibitors and Activators;Pfizer compounds;API;AG 013736 |
| Mol File: | 319460-85-0.mol |
|
|
|
| Axitinib Chemical Properties |
| mp | 213-215°C |
| storage temp. | -20°C Freezer |
| CAS DataBase Reference | 319460-85-0(CAS DataBase Reference) |
| Axitinib Usage And Synthesis |
| FDA approved axitinib use of treating advanced kidney cancer |
January 27, 2012, the FDA approved axitinib for the treatment of advanced kidney cancer (renal cell carcinoma) which other drugs unanswer . Inlyta is manufactured and sold by Pfizer,and is a oral pill taken twice a day. Renal cell carcinoma is a type of tumor originating from the tubular endothelial cells. Axitinib can prevent certain protein called kinases playing a role in tumor growth and metastasis . Axitinib is a small molecule tyrosine kinase inhibitor, effective against multiple targets, including VEGF receptors 1, 2 and 3. Dr. Richard Pazdur, hematology and oncology drugs office director of FDA Drug Evaluation and Research Centre, said: "This is the seven kind of drugs allowed treating metastatic or advanced renal cell carcinoma since 2005 . Overall, during this time ,record level of drug development has dramatically changed the treatment of metastatic renal cell carcinoma paradigm, and offers a variety of treatment options for patients. " In recent years, the drug has been approved for the treatment of kidney cancer include sorafenib (2005), sunitinib (2006), temsirolimus(2007), everolimus (2009), bevacizumab(2009) and pazopanib(2009). The above information is edited by the chemicalbook of Tian Ye. |
| Chemical Properties | Off-White Solid |
| Usage | A tyrosine kinase inhibitor; used in cancer therapy. |
| Usage | Axitinib (AG-013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. |
| Usage | Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively. |
| Usage | Axitinib is a tyrosine kinase inhibitor. Axitinib is used in cancer therapy. |
Service we provide:
1. Mixed container, we can mix different items in one container.
2. Quality control, before shipment, free sample for test. after shipment, keep sample for 3 years
3. Prompt shipment with professional documents
4. Packing as your request, with photo before shipment
| Pazopanib Basic information |
| Product Name: | Pazopanib |
| Synonyms: | Pazopanib for research;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;Pazopanib;Pazopanib(GW786034);5-(4-((2,3-diMethyl-3,3a-dihydro-2H-indazol-6-yl)(Methyl)aMino)pyriMidin-2-ylaMino)-2-MethylbenzenesulfonaMide;5-[(4-{[(2,3-diMethyl-2H-indazol-6-yl)Methyl]aMino}pyriMidin-2-yl)aMino]-2-Methylbenzene-1-sulfonaMide;5-({4-[(2,3-diMethyl-2H-indazol-6-yl)(Methyl)aMino]pyriMidin-2-yl}aMino)-2-MethylbenzenesulfonaMide 5-(4-(N-(2,3-diMethyl-2H-indazole-6-yl)- N-MethylaMino)pyriMidine-2-ylaMino)-2-MethylbenzenesulfonaMide;Votrient |
| CAS: | 444731-52-6 |
| MF: | C21H23N7O2S |
| MW: | 437.52 |
| EINECS: | |
| Product Categories: | Intermediates & Fine Chemicals;Pharmaceuticals;HFC80010;Inhibitors |
| Mol File: | 444731-52-6.mol |
|
|
|
| Pazopanib Chemical Properties |
| mp | 285-289°C (dec.) |
| density | 1.40 |
| storage temp. | Refrigerator |
| Safety Information |
| Pazopanib Usage And Synthesis |
| product description |
Pazopanib is researched and developed by a GlaxoSmithKline ,it is a novel oral vascular generation inhibitor which may interfere stubborn tumor survival and new blood vessels generation growth needed .Targeting vascular endothelial growth factor receptor (VEGFR),it works by inhibiting angiogenesis of tumor blood supply.it is suitable for advanced renal cell carcinoma ( a discovery of cancer cells in the renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC) treatment. Minnesota Rochester, Mayo Clinical Research Clinical Research Center researches show that pazopanib (trade name Votrient) can effectively cure thyroid cancer,and can make half of the patients tumor volume reduced, compared to the commonly used drugs ,it is more prolonged stable ,and can be maintained for a considerable period of treatment, the drug has the highest response rate in treatment of thyroid cancer so far. The US Food and Drug Administration (FDA) approved on October 19, 2009 that pazopanib (trade name Votrient) is listed ,the sixth approved drug treatment of kidney cancer since 2005. In 2009, approximately 49,000 patients were diagnosed with renal cell carcinoma, 11,000 patients died of the disease. June 15, 2010, pazopanib, EU conditionally approved it for advanced renal cell cancer and first-line treatment in patients with previously received cytokine therapy. Once the European Commits to give final marketing authorization for this drug, GlaxoSmithKline will have exclusive marketing rights pazopanib for ten years. |
| The efficacy of the treatment of advanced renal cell carcinoma |
In order to investigate the efficacy of molecule targeting drug tyrosine kinase inhibitor pazopanib which inhibist the angiogenesis in patients with advanced renal cell carcinoma, People's Liberation Army General Hospital, in June 2006 to May 2007, the participation of pazopanib in patients with advanced renal cell carcinoma randomized clinical drug trials of outpatient 14 cases, were divided into pazopanib group (n = 10) and placebo group ( 4 cases), were treated with pazopanib 800mg / d and placebo after 12 weeks of treatment duration, according to the results of CT scan before and after medication , efficacy was determined . The results showed that the reduced average ratios of measurable disease focus of pazopanib and placebo patients were 27.6%, - 2.8% (P The above information is edited by the chemicalbook of Tian Ye. |
| Adverse reactions |
Diarrhea, hypertension, hair color change, nausea, loss of appetite, vomiting, fatigue, weakness, headache, abdominal pain and so on. Cause serious liver problems, so health care workers should take blood tests to monitor liver function before using the drug in patients and during treatment of patients. Hazardous to the fetus,people during pregnancy are forbid using this drug. Pazopanib can also lead to arrhythmias, during treatment patients should have regular electrocardiogram measuring heart rate, and regular blood tests to monitor electrolytes since an electrolyte imbalance will also play a role in arrhythmia. |
| Chemical Properties | Off-White Solid |
| Usage | Pazopanib Hydrochloride (GW786034, Votrient, Armala) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively. |
| Usage | Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR-α/β, and c-Kit. |
| Usage | Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively. |
| Usage | An oral angiogenesis inhibitor targeting VEGFR and PDGFR. |
We have clients throughout the world：
Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet your desire.
Our Laboratoy
We have our own independent lab test center：
This makes sure that our technology support is reliable and authoritative.All of self-owned fine chemicals are manufactured strictly in accordance with international standard.,and also has scientific cooperation with local colleges and institutes.
Our factory
High quality with competitive price：
We are manufacturer and can provide high quality products with factory price
Package & Shipment
Fast and safe delivery：
Parcels can be sent out within 24 hours after payment. Tracking number is available
Secure and discreet shipment. You have various choices of transportation methods
